Patent ID: 6828330
Filing Date: 2004-12-07
Classification: A61P,C07D

Abstract:
A compound of the Formula I: wherein W0 is a bicyclic moiety and is X is O, or S; R1 is H, alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl; R2 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; R3 is H, F, alkyl, halogenated alkyl, substituted alkyl, lactam heterocycloalkyl, phenoxy, substituted phenoxy, R7, R9, â€”N(R4)-aryl, â€”O-substituted phenyl, â€”O-substituted naphthyl, â€”S-substituted phenyl, â€”S-substituted naphthyl, alkyl substituted on the &ohgr; carbon with naphthyl, or alkyl substituted on the &ohgr; carbon with substituted naphthyl; W is C(H) where Vâ€”Zâ€”Y is selected from Oâ€”C(R3)&boxH;N, Oâ€”C(R5)(R3)â€”N(R4), Oâ€”C(R5)(R3)â€”S, Oâ€”N&boxH;C(R5), Oâ€”C(R3)(R8)â€”O, Sâ€”C(R3)&boxH;N, Sâ€”C(R5)(R3)â€”N(R4), Sâ€”N&boxH;C(R5), N&boxH;C(R3)â€”O, N&boxH;C(R3)â€”S, N&boxH;C(R3)â€”N(R4), N(R4)â€”N&boxH;C(R5), N(R4)â€”C(R5)(R3)â€”O, N(R4)â€”C(R5)(R3)â€”S, N(R4)â€”C(R5)(R3)â€”N(R4), C(R5)2â€”Oâ€”N(R4), C(R5)2â€”N(R4)â€”O, C(R5)2â€”N(R4)â€”S, C(R5)&boxH;Nâ€”O, C(R5)&boxH;Nâ€”S, C(R5)&boxH;Nâ€”N(R4), C(R5)2â€”Oâ€”C(R5)2, C(R5)2â€”Sâ€”C(R5)2, C(R5)2â€”N(R4) â€”C(R5)2, or C(R5)(R17)â€”C(R3)(R17)â€”C(R5)(R17); Q is N(R19), O, or S; W is N where Vâ€”Zâ€”Y is selected from Oâ€”C(R3)&boxH;N, Oâ€”C(R5)(R3)â€”N(R4), Oâ€”C(R5)(R3)â€”S, Oâ€”N&boxH;C(R5) Oâ€”C(R3)(R5)â€”O, Sâ€”C(R3)&boxH;N, Sâ€”C(R5)(R3)â€”N(R4), Sâ€”N&boxH;C(R5), N&boxH;C(R3)â€”O, N&boxH;C(R3)â€”S, N&boxH;C(R3)â€”N(R4), N(R4)â€”N&boxH;C(R5), N(R4)â€”C(R5)(R3)â€”O, N(R4)â€”C(R5)(R3)â€”S, N(R4)â€”C(R5)(R3)â€”N(R4), C(R5)2â€”Oâ€”N(R4), C(R5)2â€”N(4)â€”O, C(R5)2â€”N(R4)â€”S, C(R5)&boxH;Nâ€”O, C(R5)&boxH;Nâ€”S, C(R5)&boxH;Nâ€”N(R4), C(R5)&boxH;C(R3)â€”C(R3)â€”C(R5)2, or C(R5)2â€”C(R3)(R5)â€”C(R5)2; R4 is H, or alkyl; R5 is H, F, Br, Cl, I, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, â€”CN, â€”NO2, â€”OR1, â€”C(O)NH2, â€”C(O)N(R16)2, â€”NHR1, â€”NR1COR16, â€”N(R10)2, â€”SR1, â€”C(O)R16, â€”CO2R1, aryl, R7, or R9; R6 is H, F, Cl, Br, I, â€”CN, â€”CF3, â€”OR16, â€”SR16, or â€”N(R16)2; R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of â€”Oâ€”, &boxH;Nâ€”, â€”N(R19)â€”, and â€”Sâ€”, and having 0-1 substituent selected from R20 and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula wherein E is O, S, or NR19, wherein E and G are independently selected from CR18, O, S, N, or NR19, and A is CR18 or N, or wherein E and G are independently selected from CR18, O, S, N, or NR19, and A is CR18 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from R20 and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;Each R8 is independently F, Br, Cl, I, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, â€”CN, â€”CF3, â€”OR1, â€”C(O)NH2, â€”NHR1, â€”SR1, â€”CO2R1, aryl phenoxy, substituted phenoxy, heteroaryl, â€”N(R4)-aryl, or â€”O-substituted aryl, R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from &boxH;Nâ€” and having 0-1 substituent selected from R20 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from &boxH;Nâ€”, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R20 and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows; Each R10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl; Each R11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; R13 is â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”C(O)NR11R11, â€”CN, â€”CF3, â€”NR11C(O)R11, â€”S(O)2NR11R11, â€”NR11S(O)2R11, or â€”NO2; R15 is aryl, R7, or R9; R16 is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl; One of R17 is H, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, â€”CN, F, Br, Cl, I, â€”OR1, â€”C(O)NH2, â€”NHR1, â€”SR1, â€”CO2R1, aryl, R7, or R9, and each of the other two R17 is independently selected from alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, â€”CN, F, Br, Cl, I, â€”OR1, â€”C(O)NH2, â€”NHR1, â€”SR1, â€”CO2R1, aryl, R7, or R9; Each R18 is independently selected from H, F, Cl, Br, I, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”NO2, â€”C(O)NR11R11, â€”CN, â€”NR11C(O)R11, â€”S(O)2NR11R11, or â€”NR11S(O)2R11, or abond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”NO2, â€”C(O)NR11R11, â€”CN, â€”NR11C(O)R11, â€”S(O)2NR11R11, or â€”NR11S(O)2R11, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I; R19 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R20 and further having 0-3 substituents independently selected from F, Cl, Br, or I; R20 is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”C(O)NR11R11, â€”CN, â€”NR11C(O)R11, â€”S(O)2NR11R11, â€”NR11S(O)2R11, â€”NO2, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R13, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R13, or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R13; Each R22 is independently H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, substituted cycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl; or pharmaceutically acceptable salt, or racemic mixture thereof.